Point72 Asset Management L.P. Buys 175,287 Shares of Quotient Ltd (NASDAQ:QTNT)

Share on StockTwits

Point72 Asset Management L.P. raised its stake in shares of Quotient Ltd (NASDAQ:QTNT) by 74.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 411,800 shares of the company’s stock after buying an additional 175,287 shares during the period. Point72 Asset Management L.P.’s holdings in Quotient were worth $3,200,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Athanor Capital LP bought a new position in shares of Quotient during the 2nd quarter valued at $182,000. JPMorgan Chase & Co. boosted its position in Quotient by 10.6% in the second quarter. JPMorgan Chase & Co. now owns 307,578 shares of the company’s stock worth $2,907,000 after purchasing an additional 29,386 shares during the last quarter. Rehmann Capital Advisory Group boosted its position in Quotient by 145.4% in the second quarter. Rehmann Capital Advisory Group now owns 41,880 shares of the company’s stock worth $392,000 after purchasing an additional 24,812 shares during the last quarter. Parallax Volatility Advisers L.P. bought a new stake in shares of Quotient during the 2nd quarter valued at about $289,000. Finally, Resources Investment Advisors LLC. grew its stake in shares of Quotient by 104.3% during the 2nd quarter. Resources Investment Advisors LLC. now owns 23,900 shares of the company’s stock valued at $224,000 after purchasing an additional 12,200 shares during the period. Institutional investors and hedge funds own 73.51% of the company’s stock.

Several equities research analysts have recently commented on QTNT shares. BidaskClub upgraded shares of Quotient from a “sell” rating to a “hold” rating in a research note on Saturday, November 16th. Zacks Investment Research downgraded shares of Quotient from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, ValuEngine upgraded shares of Quotient from a “sell” rating to a “hold” rating in a research report on Tuesday, November 19th.

In related news, major shareholder Perceptive Advisors Llc bought 2,500,000 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were bought at an average cost of $7.00 per share, for a total transaction of $17,500,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 14.20% of the stock is currently owned by insiders.

Shares of Quotient stock opened at $8.60 on Tuesday. Quotient Ltd has a 1-year low of $5.73 and a 1-year high of $11.30. The company’s fifty day simple moving average is $8.20 and its 200-day simple moving average is $9.04. The company has a debt-to-equity ratio of 72.27, a current ratio of 3.97 and a quick ratio of 3.25. The stock has a market capitalization of $571.35 million, a PE ratio of -4.48 and a beta of 0.96.

Quotient (NASDAQ:QTNT) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). The firm had revenue of $7.85 million during the quarter, compared to analysts’ expectations of $6.80 million. As a group, research analysts anticipate that Quotient Ltd will post -1.58 EPS for the current year.

Quotient Profile

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.

See Also: How to Invest in Growth Stocks

Want to see what other hedge funds are holding QTNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quotient Ltd (NASDAQ:QTNT).

Institutional Ownership by Quarter for Quotient (NASDAQ:QTNT)

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.